Skip Navigation

Alectinib Tablets Added To Adalvo's Product List

26 March 2024

Adalvo proudly announces the addition of Alectinib 300, 450, and 600mg tablets to our product list.

Our product, being developed based on the reference brand Alecensa 150mg hard capsules, will serve as a vital treatment for adult patients with Anaplastic Lymphoma Kinase (ALK)-positive advanced Non-Small Cell Lung Cancer (NSCLC). 

The availability of multiple tablet strengths will significantly contribute to patient compliance, reducing the burden of taking multiple capsules. By consolidating the dose into a single tablet, it will become more convenient for patients to follow their prescribed dosage regime.

In 2023, the brand achieved global sales of approximately $1.5 billion, with a Global 3-year Compound Annual Growth Rate (CAGR) of 4%, as reported by IQVIA.

Adalvo's commitment to oncology extends across its entire portfolio, with a focus on delivering high-quality and effective treatments.

At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.

Click Here To Get In Touch!